Gupta S, Heemers HV. Treatment-induced treatment sensitization in metastatic castration-resistant prostate cancer. Eur Urol. 2021;79:734–5.
Google Scholar
Yin L, Hu Q. CYP17 inhibitors–abiraterone, C17,20-lyase inhibitors and multi-targeting agents. Nat Rev Urol. 2014;11:32–42.
Google Scholar
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352–60.
Google Scholar
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.
Google Scholar
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.
Google Scholar
Giacinti S, Bassanelli M, Aschelter AM, Milano A, Roberto M, Marchetti P. Resistance to abiraterone in castration-resistant prostate cancer: a review of the literature. Anticancer Res. 2014;34. https://pubmed.ncbi.nlm.nih.gov/25368223/.
Gurioli G, Conteduca V, Lolli C, Schepisi G, Gargiulo S, Altavilla A, et al. Plasma AR copy number changes and outcome to abiraterone and enzalutamide. Front Oncol. 2020;10:567809.
Google Scholar
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028–38.
Google Scholar
Nuclear translocation of RON receptor tyrosine kinase. New mechanistic and functional insights – PubMed. 2025. https://pubmed.ncbi.nlm.nih.gov/39794156/.
Yao H-P, Zhou Y-Q, Zhang R, Wang M-H. MSP-RON signalling in cancer: pathogenesis and therapeutic potential. Nat Rev Cancer. 2013;13:466–81.
Google Scholar
Gray JK, Paluch AM, Stuart WD, Waltz SE. Ron receptor overexpression in the murine prostate induces prostate intraepithelial neoplasia. Cancer Lett. 2012;314:92–101.
Google Scholar
Brown NE, Paluch AM, Nashu MA, Komurov K, Waltz SE. Tumor cell autonomous RON receptor expression promotes prostate cancer growth under conditions of androgen deprivation. Neoplasia. 2018;20:917–29.
Google Scholar
Brown NE, Jones A, Hunt BG, Waltz SE. Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling. Prostate. 2022;82:1422–37.
Google Scholar
Zhang H, Kong L, Li J, Liu Z, Zhao Y, Lv X, et al. SPOP mutations increase PARP inhibitor sensitivity via CK2/PIAS1/SPOP axis in prostate cancer. JCI Insight. 2025;10:e186871.
Google Scholar
Santoni M, Büttner T, Rescigno P, Fiala O, Cavasin N, Basso U, et al. Apalutamide in metastatic castration-sensitive prostate cancer: results from the multicenter real-world ARON-3 study. Eur Urol Oncol. 2025;8:444–51.
Google Scholar
Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368:1314–25.
Google Scholar
Chowdhury S, Bjartell A, Agarwal N, Chung BH, Given RW, Pereira de Santana Gomes AJ, et al. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. Ann Oncol. 2023;34:477–85.
Google Scholar
Chen J-F, Yu B-X, Ma L, Lv X-Y, Jiang J-H, Ma Q. RON is overexpressed in bladder cancer and contributes to tumorigenic phenotypes in 5637 cells. Oncol Lett. 2018;15:6547–54.
Google Scholar
Wang K-J, Wang K-Y, Zhang H-Z, Meng X-Y, Chen J-F, Wang P, et al. Up-regulation of RIP3 alleviates prostate cancer progression by activation of RIP3/MLKL signaling pathway and induction of necroptosis. Front Oncol. 2020;10:1720.
Google Scholar
Wang K-J, Ye S-Z, Jia X-L, Wang K-Y, Meng X-Y, Fei X, et al. RON receptor tyrosine kinase as a critical determinant in promoting tumorigenic behaviors of bladder cancer cells through regulating MMP12 and HIF-2α pathways. Cell Death Dis. 2024;15:844.
Google Scholar
Wu X, Zhou Z, Xu S, Liao C, Chen X, Li B, et al. Extracellular vesicle packaged LMP1-activated fibroblasts promote tumor progression via autophagy and stroma-tumor metabolism coupling. Cancer Lett. 2020;478:93–106.
Google Scholar
CUT&Tag for efficient epigenomic profiling of small samples and single cells – PubMed. 2026. https://pubmed.ncbi.nlm.nih.gov/31036827/.
Hoang N-M, Liu Y, Bates PD, Heaton AR, Lopez AF, Liu P, et al. Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma. Cell Rep Med. 2024;5:101484.
Google Scholar
Leuthner TC, Hartman JH, Ryde IT, Meyer JN. PCR-based determination of mitochondrial DNA copy number in multiple species. Methods Mol Biol. 2021;2310:91–111.
Google Scholar
Cordier C, Haustrate A, Mihalache A, Duval E, Desruelles E, Spriet C, et al. Targeting TRPV6/CXCR4 complexes prevents castration-resistant prostate cancer metastasis to the bone. Signal Transduct Target Ther. 2025;10:287.
Google Scholar
Chen D, Yu J, Zhang L. Necroptosis: an alternative cell death program defending against cancer. Biochim Biophys Acta. 2016;1865:228–36.
Google Scholar
Jeltsch A, Jurkowska RZ. New concepts in DNA methylation. Trends Biochem Sci. 2014;39:310–8.
Google Scholar
Farah E, Zhang Z, Utturkar SM, Liu J, Ratliff TL, Liu X. Targeting DNMTs to overcome enzalutamide resistance in prostate cancer. Mol Cancer Ther. 2022;21:193–205.
Google Scholar
Cazes A, Childers BG, Esparza E, Lowy AM. The MST1R/RON tyrosine kinase in cancer: oncogenic functions and therapeutic strategies. Cancers. 2022;14:2037.
Google Scholar
Meng Q, Xia Y. c-Jun, at the crossroad of the signaling network. Protein Cell. 2011;2:889–98.
Google Scholar
Lipka DB, Witte T, Toth R, Yang J, Wiesenfarth M, Nöllke P, et al. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. Nat Commun. 2017;8:2126.
Google Scholar
Yao H-P, Tong X-M, Hudson R, Wang M-H. MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy. J Exp Clin Cancer Res. 2020;39:198.
Google Scholar
Weng T, Yan D, Shi D, Zhu M, Liu Y, Wu Z, et al. The MSP-RON pathway regulates liver fibrosis through transforming growth factor beta-dependent epithelial-mesenchymal transition. Liver Int. 2021;41:1956–68.
Google Scholar
Bezwada D, Perelli L, Lesner NP, Cai L, Brooks B, Wu Z, et al. Mitochondrial complex I promotes kidney cancer metastasis. Nature. 2024;633:923–31.
Google Scholar
Mishra P, Chan DC. Mitochondrial dynamics and inheritance during cell division, development and disease. Nat Rev Mol Cell Biol. 2014;15:634–46.
Google Scholar
Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701–11.
Google Scholar
Mostaghel EA, Marck BT, Plymate S, Vessella R, Balk S, Matsumoto AM, et al. Resistance to CYP17A1 inhibition with abiraterone in castration resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011;17:5913–25.
Google Scholar
Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19:575–86.
Google Scholar
Cai M, Song X-L, Li X-A, Chen M, Guo J, Yang D-H, et al. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updat. 2023;68:100962.
Google Scholar
Thobe MN, Gurusamy D, Pathrose P, Waltz SE. The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells. Oncogene. 2010;29:214–26.
Google Scholar
Batth IS, Yun H, Kumar AP. Recepteur d’origine nantais (RON), more than a kinase: role in castrate-resistant prostate cancer. Mol Carcinog. 2015;54:937–46.
Google Scholar
Sullivan C, Brown NE, Vasiliauskas J, Pathrose P, Starnes SL, Waltz SE. Prostate epithelial RON signaling promotes M2 macrophage activation to drive prostate tumor growth and progression. Mol Cancer Res. 2020;18:1244–54.
Google Scholar
Wu X-N, Yang Z-H, Wang X-K, Zhang Y, Wan H, Song Y, et al. Distinct roles of RIP1-RIP3 hetero- and RIP3-RIP3 homo-interaction in mediating necroptosis. Cell Death Differ. 2014;21:1709–20.
Google Scholar
Wang H, Sun L, Su L, Rizo J, Liu L, Wang L-F, et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell. 2014;54:133–46.
Google Scholar
Tan Y, Sementino E, Cheung M, Peri S, Menges CW, Kukuyan A-M, et al. Somatic epigenetic silencing of RIPK3 inactivates necroptosis and contributes to chemoresistance in malignant mesothelioma. Clin Cancer Res. 2021;27:1200–13.
Google Scholar
Yin B, Liu Z, Wang Y, Wang X, Liu W, Yu P, et al. RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells. Oncol Rep. 2017;37:3209–18.
Google Scholar
Wagh PK, Peace BE, Waltz SE. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res. 2008;100:1–33.
Google Scholar
Guo N, Li MZ, Wang LM, Chen HD, Song SS, Miao ZH, et al. Repeated treatments of Capan-1 cells with PARP1 and Chk1 inhibitors promote drug resistance, migration and invasion. Cancer Biol Therapy. 2022;23. https://doi.org/10.1080/15384047.2021.2024414.
Puhr M, Hoefer J, Schäfer G, Erb HHH, Oh SJ, Klocker H, et al. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol. 2012;181:2188–201.
Google Scholar
Massoner P, Thomm T, Mack B, Untergasser G, Martowicz A, Bobowski K, et al. EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205. Br J Cancer. 2014;111:955–64.
Google Scholar
Ma Q, Guin S, Padhye SS, Zhou Y-Q, Zhang R-W, Wang M-H. Ribosomal protein S6 kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein. Mol Cancer. 2011;10:66.
Google Scholar
Kaito S, Aoyama K, Oshima M, Tsuchiya A, Miyota M, Yamashita M, et al. Inhibition of TOPORS ubiquitin ligase augments the efficacy of DNA hypomethylating agents through DNMT1 stabilization. Nat Commun. 2024;15. https://doi.org/10.1038/s41467-024-50498-4.
Dussault I, Bellon SF. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer. Anticancer Agents Med Chem. 2009;9:221–9.
Google Scholar
Kawada I, Hasina R, Arif Q, Mueller J, Smithberger E, Husain AN, et al. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Res. 2014;74:884–95.
Google Scholar
Chakedis J, French R, Babicky M, Jaquish D, Howard H, Mose E, et al. A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells. Oncogene. 2016;35:3249–59.
Google Scholar
